Association between SOD2 V16A variant and urological cancer risk

The correlation between superoxide dismutase 2 (SOD2) V16A variant and urological cancer susceptibility has been widely studied, however, with divergent results. Totally, 9,910 cancer patients and 11,239 control subjects were enrolled. V16A variant is associated with an increased susceptibility to u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aging (Albany, NY.) Jg. 12; H. 1; S. 825
Hauptverfasser: Zhang, Li-Feng, Xu, Kai, Tang, Bo-Wen, Zhang, Wei, Yuan, Wei, Yue, Chuang, Shi, Li, Mi, Yuan-Yuan, Zuo, Li, Zhu, Li-Jie
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 12.01.2020
Schlagworte:
Adult
Aged
Alleles
Biomarkers, Tumor
Computational Biology - methods
DNA Methylation
Epistasis, Genetic
Female
Gene Expression Profiling
Gene Frequency
Genetic Association Studies
Genetic Predisposition to Disease
Genetic Variation
Genotype
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Odds Ratio
Prognosis
Promoter Regions, Genetic
Publication Bias
Risk Assessment
Risk Factors
Superoxide Dismutase - genetics
Transcriptome
Urologic Neoplasms - genetics
Urologic Neoplasms - mortality
variant
in silico
SOD2
analysis
urological cancer
ISSN:1945-4589, 1945-4589
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The correlation between superoxide dismutase 2 (SOD2) V16A variant and urological cancer susceptibility has been widely studied, however, with divergent results. Totally, 9,910 cancer patients and 11,239 control subjects were enrolled. V16A variant is associated with an increased susceptibility to urological cancer (A-allele vs. V-allele: OR = 1.06, 95% CI = 1.00 - 1.13, = 0.047; AA+AV vs. VV: OR = 1.09, 95% CI = 1.02 - 1.16, = 0.008), especially for prostate cancer (PCa). Serum SOD2 level of PCa patients with VV+VA genotypes was lower than in those with AA genotypes. SOD2 expression is downregulated in both prostate and bladder cancer, as compared to the control. Furthermore, SOD2 was found to be downregulated in more advanced PCa participants, as compared to the ones in early stages. PCa subjects with low SOD2 expression displayed a shorter disease-free survival (DFS) time compared to that of the high SOD2 expression counterparts. The SOD2 V16A variant may be associated with increased urological cancer susceptibility, especially for prostate cancer. A pooled analysis utilizing odds ratios (ORs), tools and ELISA was adopted to demonstrate this association. We also used immunohistochemical staining (IHS) to assess SOD2 expression.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1945-4589
1945-4589
DOI:10.18632/aging.102658